Rite Aid (RAD) Scheduled to Post Earnings on Thursday
Rite Aid (NYSE:RAD) is scheduled to post its Q115 quarterly earnings results on Thursday, June 19th. Analysts expect Rite Aid to post earnings of $0.05 per share and revenue of $6.43 billion for the quarter. Rite Aid has set its FY15 guidance at $0.31-0.42 EPS.
Rite Aid (NYSE:RAD) last posted its quarterly earnings results on Thursday, April 10th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.06. The company had revenue of $6.60 billion for the quarter, compared to the consensus estimate of $6.54 billion. During the same quarter in the previous year, the company posted $0.13 earnings per share. The company’s revenue for the quarter was up 2.2% on a year-over-year basis. On average, analysts expect Rite Aid to post $0.35 EPS for the current fiscal year and $0.48 EPS for the next fiscal year.
Rite Aid (NYSE:RAD) opened at 7.16 on Wednesday. Rite Aid has a one year low of $2.62 and a one year high of $8.62. The stock has a 50-day moving average of $7.75 and a 200-day moving average of $6.52. The company has a market cap of $6.955 billion and a price-to-earnings ratio of 30.93.
Several analysts have recently commented on the stock. Analysts at S&P Equity Research downgraded shares of Rite Aid to a “sell” rating in a research note on Friday, June 6th. On the ratings front, analysts at Goldman Sachs reiterated a “buy” rating on shares of Rite Aid in a research note on Thursday, June 5th. Finally, analysts at Credit Suisse reiterated an “outperform” rating on shares of Rite Aid in a research note on Friday, May 23rd. They now have a $8.50 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. Rite Aid currently has an average rating of “Buy” and an average price target of $7.75.
Rite Aid Corporation is a retail drugstore chain in the United States. In the Company’s stores, it sells prescription drugs and a range of other merchandise, which it calls front end products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.